Please ensure Javascript is enabled for purposes of website accessibility

Why Rigel Is Poised to Bounce Back

By Brian D. Pacampara, CFA - Apr 8, 2013 at 9:46AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Market-trouncing returns could be written in this 4-star stock.

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, clinical-stage drug development company Rigel Pharmaceuticals (RIGL -1.49%) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Rigel and see what CAPS investors are saying about the stock right now.

Rigel facts

Headquarters (founded)

South San Francisco, Calif. (1996)

Market Cap

$392.1 million



Trailing-12-Month Revenue

$2.3 million


Chairman/CEO James Gower
President/COO Raul Rodriguez

Return on Equity (average, past 3 years)



$298.2 million / $0



Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 97% of the 891 members who have rated Rigel believe the stock will outperform the S&P 500 going forward.

Just this past Friday, one of those Fools, All-Star zzlangerhans, tapped Rigel as a particularly attractive bargain opportunity:

The street responded to news of mixed results of the OSKIRA-1 phase III trial of fostamatinib ... as though the trial was an unequivocal failure. In fact, the trial failed to show improvement over placebo in RA by radiographic criteria but did show stat sig improvement by clinical criteria. If this type of outcome holds through subsequent trials the company and partner AstraZeneca may submit an NDA on the basis that clinical improvement trumps radiographic improvement.

As of the end of 2012, Rigel has about [$300M] in liquid assets to support a market cap of [$392M] at [Friday's] close. That's a reasonable bet for a rebound, although my personal preference would have been to let the stock get beaten up further when OSKIRA-2 and OSKIRA-3 results are released later this quarter, and then hopefully mop up closer to cash.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Rigel Pharmaceuticals, Inc. Stock Quote
Rigel Pharmaceuticals, Inc.
$1.98 (-1.49%) $0.03
Amgen Inc. Stock Quote
Amgen Inc.
$249.04 (0.62%) $1.54

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.